scholarly journals Mechanisms Underlying the Analgesic Effect of Moxibustion on Visceral Pain in Irritable Bowel Syndrome: A Review

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Renjia Huang ◽  
Jimeng Zhao ◽  
Luyi Wu ◽  
Chuanzi Dou ◽  
Huirong Liu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Visceral Pain ◽  
Epidemiological Data ◽  
Neuroendocrine System ◽  
Functional Bowel Disorder ◽  
Number Of Patients ◽  
Potential Problems ◽  
Irritable Bowel ◽  
Bowel Disorder

Irritable bowel syndrome (IBS) is a functional bowel disorder that causes recurrent abdominal (visceral) pain. Epidemiological data show that the incidence rate of IBS is as high as 25%. Most of the medications may lead to tolerance, addiction and toxic side effects. Moxibustion is an important component of traditional Chinese medicine and has been used to treat IBS-like abdominal pain for several thousand years in China. As a mild treatment, moxibustion has been widely applied in clinical treatment of visceral pain in IBS. In recent years, it has played an irreplaceable role in alternative medicine. Extensive clinical studies have demonstrated that moxibustion for treatment of visceral pain is simple, convenient, and inexpensive, and it is being accepted by an increasing number of patients. There have not been many studies investigating the analgesic mechanisms of moxibustion. Studies exploring the analgesic mechanisms have mainly focused on visceral hypersensitivity, brain-gut axis neuroendocrine system, and immune system. This paper reviews the latest developments in moxibustion use for treatment of visceral pain in IBS from these perspectives. It also evaluates potential problems in relevant studies on the mechanisms of moxibustion therapy to promote the application of moxibustion in the treatment of IBS.

scholarly journals The role of abuse in the development of irritable bowel syndrome: a comparative study

2003 ◽  
Vol 8 (4) ◽  
pp. 88-98
Author(s):  
G Eileen Rossouw ◽  
Anita D Stuart ◽  
H Gertie Pretorius
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Comparative Study ◽  
Full Text ◽  
Bowel Habit ◽  
Functional Bowel Disorder ◽  
Irritable Bowel ◽  
Bowel Disorder

Irritable Bowel Syndrome (IBS) is defined as a chronic relapsing functional bowel disorder of unknown causes which is characterised by attacks of abdominal pain and change of bowel habit resulting in diarrhoea or constipation or both. Opsomming Prikkelbare Dermsindroom (PDS) word gedefinieer as ’n chroniese, herhalende, funksionele ingewandsversteuring wat gekenmerk word deur aanvalle van buikpyn en ‘n verandering in ingewandsgewoontes, wat diarree of hardlywigheid, of beide, tot gevolg het. *Please note: This is a reduced version of the abstract. Please refer to PDF for full text.

scholarly journals PATOGENESIS DAN DIAGNOSIS SINDROM KOLON IRITABEL

2012 ◽  
Vol 4 (3) ◽  
Author(s):  
Edwin Jim
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Visceral Hypersensitivity ◽  
Enteric Infection ◽  
Functional Bowel Disorder ◽  
Bowel Habits ◽  
Infection Diagnosis ◽  
Rome Iii ◽  
Irritable Bowel ◽  
Bowel Disorder

Abstract: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder characterized by abdominal pain or discomfort and alterations in bowel habits. Many factors play some important roles in the development of the IBS including abnormal motility, visceral hypersensitivity, and enteric infection. Diagnosis of IBS is based on Rome III criteria.Keywords: irritable bowel syndrome, pathogenesis, diagnosisAbstrak: Sindrom kolon iritabel (SKI) adalah penyakit gastrointestinal fungsional kronik yang ditandai oleh nyeri perut atau rasa tidak enak di perut dan gangguan kebiasaan defekasi. Banyak faktor yang menyebabkan terjadinya SKI antara lain gangguan motilitas, hipersensitivitas viseral, dan pasca infeksi usus. Saat ini kriteria diagnosis yang digunakan untuk SKI ialah kriteria Roma III.Kata kunci: sindrom kolon iritabel, patogenesis, diagnosis

scholarly journals Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome

2021 ◽  
Vol 11 ◽  
Author(s):  
Lin Xiao ◽  
Qin Liu ◽  
Mei Luo ◽  
Lishou Xiong
Keyword(s):  
Amino Acids ◽  
Fatty Acids ◽  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Short Chain Fatty Acids ◽  
Functional Bowel Disorder ◽  
Irritable Bowel ◽  
The Brain ◽  
Bowel Disorder

Irritable bowel syndrome (IBS) is the most common functional bowel disorder worldwide and is associated with visceral hypersensitivity, gut motility, immunomodulation, gut microbiota alterations, and dysfunction of the brain-gut axis; however, its pathophysiology remains poorly understood. Gut microbiota and its metabolites are proposed as possible etiological factors of IBS. The aim of our study was to investigate specific types of microbiota-derived metabolites, especially bile acids, short-chain fatty acids, vitamins, amino acids, serotonin and hypoxanthine, which are all implicated in the pathogenesis of IBS. Metabolites-focused research has identified multiple microbial targets relevant to IBS patients, important roles of microbiota-derived metabolites in the development of IBS symptoms have been established. Thus, we provide an overview of gut microbiota and their metabolites on the different subtypes of IBS (constipation-predominant IBS-C, diarrhea-predominant IBS-D) and present controversial views regarding the role of microbiota in IBS.

scholarly journals Functional constipation masked as irritable bowel syndrome

2020 ◽  
Author(s):  
Monica Tosto ◽  
Paola D’Andrea ◽  
Ignazio Salamone ◽  
Salvatore Pellegrino ◽  
Stefano Costa ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Functional Gastrointestinal Disorders ◽  
Functional Constipation ◽  
Control Group ◽  
Number Of Patients ◽  
Erroneous Diagnosis ◽  
Irritable Bowel ◽  
Mixed Pattern ◽  
Rome Iv

Abstract Background: Rome IV criteria for functional gastrointestinal disorders state that children suspected of having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C) should be preliminarily treated for constipation. We aimed at verifying if functional constipation may indeed lead to an erroneous diagnosis of IBS with diarrhea (IBS-D) or IBS with mixed pattern of diarrhea and constipation (IBS-M). Methods: We prospectively enrolled in an unblinded fashion 10 and 16 consecutive children referred to our center who met Rome IV criteria for a diagnosis of IBS-D and IBS-M, respectively. Patients who fulfilled criteria for suspect “occult constipation” were then given a bowel cleaning regimen with Polyethylene glycol 3350, re-evaluated at 2 months and followed up for at least 6 months. Sixteen additional patients with IBS with Constipation (IBS-C) referred in the same period served as control. The endpoints were: 1) a decrease of more than 50% in abdominal pain intensity and frequency scores; and 2) for patients with IBS-D and IBS-M: resolution of diarrhea. Results: The endpoints were met by 8 (80%) and 14 (87%) of the patients with IBS-D and IBS-M, respectively, with decrease of abdominal pain and resolution of “diarrhea”. The response was not significantly different from that observed in 15 (93%) of the IBS-C control group. Conclusion: Acknowledging the limitations of the small number of patients and of the uncontrolled nature of the study, we suggest that a possibly large number of patients labeled as IBS-D or IBS-M may actually simply present functional constipation and should be managed as such.

scholarly journals Arrowroot as a treatment for diarrhoea in irritable bowel syndrome patients: a pilot study

2000 ◽  
Vol 37 (1) ◽  
pp. 20-24 ◽  
Author(s):  
Caroline COOKE ◽  
Irene CARR ◽  
Keith ABRAMS ◽  
John MAYBERRY
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Pilot Study ◽  
Term Effect ◽  
Treatment Results ◽  
Long Term Effect ◽  
Number Of Patients ◽  
Bowel Action ◽  
Irritable Bowel

Objectives - Arrowroot is an old-fashioned remedy for diarrhoea, but no clinical studies have been done to evaluate its effectiveness. The aim of this pilot study was to assess its efficacy as a treatment for diarrhoea in 11 patients, all of whom had irritable bowel syndrome with diarrhoea as a feature. Methods - The patients were interviewed and a questionnaire completed on entry into the trial. They then took 10 mL arrowroot powder three times a day for one month and discontinued the treatment for the subsequent month. Questionnaires were completed after one month on treatment and at the end of the trial after one month off treatment. Results - Arrowroot reduced diarrhoea and had a long-term effect on constipation. It also eased abdominal pain. Conclusion - Arrowroot is an effective treatment for diarrhoea. Its action could be explained by several theories which relate to an increase in faecal bulk and thus a more efficient bowel action. The number of patients was small, and further studies are needed to substantiate preliminary results.

scholarly journals Functional constipation masked as irritable bowel syndrome

2020 ◽  
Author(s):  
Monica Tosto ◽  
Paola D’Andrea ◽  
Ignazio Salamone ◽  
Salvatore Pellegrino ◽  
Stefano Costa ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Functional Gastrointestinal Disorders ◽  
Functional Constipation ◽  
Gastrointestinal Disorders ◽  
Number Of Patients ◽  
Erroneous Diagnosis ◽  
Irritable Bowel ◽  
Mixed Pattern ◽  
Rome Iv

Abstract Background Rome IV criteria for functional gastrointestinal disorders state that children suspected of having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C) should be preliminarily treated for constipation. We aimed at verifying if functional constipation may indeed lead to an erroneous diagnosis of IBS with diarrhea (IBS-D) or IBS with mixed pattern of diarrhea and constipation (IBS-M).Methods We prospectively enrolled in an unblinded fashion 10 and 16 consecutive children referred to our center who met Rome IV criteria for a diagnosis of IBS-D and IBS-M, respectively. Patients who fulfilled criteria for suspect “occult constipation” were then given a bowel cleaning regimen with PEG 3350, re-evaluated at 2 months and followed up for at least 6 months. Sixteen additional patients with IBS with Constipation (IBS-C) referred in the same period served as control. The endpoints were: 1) a decrease of more than 50% in abdominal pain intensity and frequency scores; and 2) for patients with IBS-D and IBS-M: resolution of diarrhea.Results The endpoints were met by 8 (80%) and 14 (87%) of the patients with IBS-D and IBS-M, respectively, with decrease of abdominal pain and resolution of “diarrhea”. The response was not significantly different from that observed in 15 (93%) of the IBS-C control group.Conclusion acknowledging the limitations of the small number of patients and of the uncontrolled nature of the study, we suggest that a possibly large number of patients labeled as IBS-D or IBS-M may actually simply present functional constipation and should be managed as such.

scholarly journals Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride?

2010 ◽  
Vol 3 ◽  
pp. CGast.S4136 ◽  
Author(s):  
Gareth J. Sanger ◽  
Eamonn M.M. Quigley
Keyword(s):  
Irritable Bowel Syndrome ◽  
Chronic Constipation ◽  
Intrinsic Activity ◽  
Functional Bowel Disorder ◽  
Prokinetic Drugs ◽  
Receptor Agonists ◽  
New Class ◽  
To Come ◽  
Irritable Bowel ◽  
Bowel Disorder

After the problems associated with the non-selective 5-HT4 receptor agonists cisapride and tegaserod, the 5-HT4 receptor is now beginning to come in from the cold. Thus, prucalopride is now the first of a new class of drug defined by selectivity and high intrinsic activity at the 5-HT4 receptor. Prucalopride has been developed for treatment of chronic constipation rather than constipation-predominant irritable bowel syndrome (IBS). This follows the trend of first evaluating new gastrointestinal (GI) prokinetic drugs in disorders where disrupted GI motility is known to exist, rather than in a functional bowel disorder where changes in motility are uncertain. If prucalopride is not progressed towards the IBS indication, it has at least shown the way for other selective 5-HT4 receptor agonists. Most notable among these is TD-5108 (velusetrag), also characterized by good selectivity at the 5-HT4 receptor, high intrinsic activity and efficacy in patients with chronic constipation.

Functional gastrointestinal diseases

2018 ◽  
Author(s):  
Satish Keshav ◽  
Alexandra Kent
Keyword(s):  
Abdominal Pain ◽  
Gastrointestinal Diseases ◽  
Chronic Abdominal Pain ◽  
Bowel Habit ◽  
Functional Bowel Disorder ◽  
Functional Abdominal Pain ◽  
Biliary Pain ◽  
Irritable Bowel ◽  
Functional Gastrointestinal Diseases ◽  
Bowel Disorder

Irritable bowel syndrome is a functional bowel disorder characterized by chronic abdominal pain associated with a change in bowel habit or stool consistency in the absence of any definite organic abnormality. It is the commonest functional gastrointestinal syndrome. Many others have been defined clinically, including functional dyspepsia, functional biliary pain, functional abdominal pain, and so on.

Sign in / Sign up

Export Citation Format

Share Document